

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



M

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/16		(11) International Publication Number: WO 99/07390
A1		(43) International Publication Date: 18 February 1999 (18.02.99)
<p>(21) International Application Number: PCT/EP98/04841</p> <p>(22) International Filing Date: 4 August 1998 (04.08.98)</p> <p>(30) Priority Data: 97113466.3 5 August 1997 (05.08.97) EP</p> <p>(71) Applicant (for all designated States except US): OC-TAPHARMA AG [CH/CH]; Haus im Park, P.O. Box, CH-8866 Ziegelbrücke (CH).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MARGUERRE, Wolfgang [DE/SE]; Wachtmeisterweg 39b, S-252 84 Helsingborg (SE). SVAE, Tor-Einar [NO/NO]; Rustad, N-2090 Hurdal (NO).</p> <p>(74) Agents: MEYERS, Hans-Wilhelm et al.; P.O. Box 10 22 41, D-50462 Cologne (DE).</p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DE, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: A UNIVERSALLY APPLICABLE BLOOD PLASMA</p> <p>(57) Abstract</p> <p>A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B, optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group O.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

A universally applicable blood plasma

The present invention is related to a universally applicable blood plasma as well as a process for preparing same.

Blood plasma is a very widely used substitute for blood losses, for example, during operation or when severe bleedings occur after accidents. Since there are four major blood groups, at present different plasmas are prepared to serve patients with the different blood groups. Obviously, this is awkward since four different blood plasma preparations have to be stored by the respective blood banks or blood centers in the hospital. Furthermore, it would be necessary to determine the blood group of the patient who is in need of a blood substitute. This delay might be critical in case of emergency.

Thus, it is one object of the invention to provide a blood plasma preparation which can be applied universally to patients with different blood groups.

The present invention provides a universally applicable blood plasma obtainable by mixing blood or blood plasma of blood groups A and B and optionally blood or blood plasma derived

from blood group AB, without admixing substantial amounts of blood or blood plasma derived from blood group 0.

The blood plasma preparation of the invention is advantageous since there will be no risk of incompatible plasma infusions which may cause severe adverse reactions which can even be lethal. Additionally, the blood plasma preparation of the invention can be located at the site of the intended use, i. e. operation rooms and emergency rooms. Hence, the end user can have access to this lifesaving product immediately on request. The respective end user does not have to wait until the product ordered from the blood centers is released. At present the blood centers have to release a blood group specific plasma according to the blood group of the recipient.

In a preferred embodiment of the present invention the AB0 blood group specific antibodies of the blood plasma are neutralized and/or removed.

A blood plasma preparation which is substantially free of fractions of group 0 leads to a more universally applicable blood plasma preparation. The blood plasma of the invention comprises preferably high amounts of blood plasma derived from donors having the blood group A, medium amounts of blood plasma derived from donors having the blood group B and optionally low amounts of blood plasma derived from donors having the blood group AB. The blood plasma of the invention is substantially free of blood plasma from donors having the blood group 0. A further preferred embodiment of the present invention is a blood plasma comprising 6 to 10 parts of blood plasma derived from donors having the blood group A, 1 to 3 parts of blood plasma derived from donors having the blood group B, and 0.0 to 1.5 parts of blood plasma derived from donors having the blood group AB and substantially no blood plasma derived from blood group 0.

In a very preferred embodiment of the present invention the blood plasma comprises 7.5 to 8.5 parts of blood plasma derived from donors having the blood group A, 1.5 to 2.5 parts of blood plasma derived from donors having the blood group B, and optionally about 1 part of blood plasma derived from donors having the blood group AB and substantially no blood or blood plasma derived from blood group 0.

Preferably, the blood plasma of the invention has been prepared by pooled plasma derived from any donors. The pooled plasma preferably has been virus inactivated. The virus inactivation can be performed prior to mixing blood or blood plasma of different blood groups A, B and AB or after preparing of the blood plasma of the present invention. For virus inactivation any methods of the art can be used, for example, virus inactivation by irradiation with actinic radiation, pasteurization, solvent detergent treatment or combinations of the method. A well known method in the art, for example, is the solvent detergent treatment as disclosed in EP-A-0 131 740 as well as the method according to WO-A-94/17834 developed by Octapharma AG, Switzerland.

The blood plasma of the invention can be stored and delivered in any state known to the skilled person. The blood plasma may contain pharmaceutically acceptable adjuvants, such as stabilizers and anticoagulants.

Preferably, the blood plasma of the invention is stored or delivered in a solid state, for example, in frozen form. Furthermore, it may be advantageous to store or deliver the blood plasma of the invention in a lyophilized or spray-dried form. In case the dried plasma is needed it can easily be dissolved in sterile water in order to infuse it in the patient.

The AB0 blood group specific antibody titre of the blood plasma of the invention is preferably lower than 16 for anti

A/anti B IgM and 64 for anti A/anti B IgG. In a very preferred embodiment the titre of the anti-A and anti-B antibodies is lower than 8 for IgM and lower than 32 for IgG.

The process for preparing the blood plasma of the invention comprises the steps of pooling blood or blood plasma of donors having the blood groups A, B and optionally AB as well as neutralizing and/or removing antibodies.

If blood is used as a starting material, blood plasma is produced from the blood pool by methods known in the art.

More than two-thirds of all blood donors have free A and/or B substance in plasma. These substances are almost identical to A and B antigens bound to the surface of red blood cells. By mixing appropriate amounts of blood or blood plasma of the blood groups A, B and optionally AB anti-A and anti-B antibodies of subclasses IgM and IgG are neutralized by binding two free A and/or B substances and/or are removed during the further processing.

Surprisingly, although the plasma of the present invention used as raw material contains both residual red blood cells and the complete complement systems there are no signs of complement activation during the production or in the final product. According to the manufacturing process it is preferred that the mixing takes place during pooling of the plasma units in the beginning of the process combined with a complete cell removal and a virus inactivation process, preferably a solvent detergent treatment. The final product can be used without limitation on the infusion rate and total dosage.

The blood plasma of the invention prepared according to the process of the invention is advantageous since it additionally is coagulation active.

The present invention is further illustrated but not limited by the following example.

Example

278 l of fresh-frozen plasma derived from blood group A, 68 l of B and 34 l of AB are mixed together and allowed to thaw. Sodium dihydrogenphosphate dihydrate is added as a buffer to stabilize the plasma proteins. After filtration through a membrane having a pore size of 1 μ m, the obtained fraction is virus inactivated by the solvent detergent method. After removal of the virus inactivating agents, glycine is added to adjust the osmolarity. During quality control the amount of free anti-A and anti-B antibodies is tested. Such tests are well-known in the art. The titre of anti-A and anti-B antibodies should be < 8 for IgM and < 32 for IgG.

Claims

1. A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group O.
2. The blood plasma of claim 1, wherein the ABO blood group specific antibodies of the blood plasma are neutralized and/or removed.
3. The blood plasma of claim 2, comprising high amounts of blood plasma derived from donors having the blood group A, medium amounts of blood plasma derived from donors having the blood group B, and optionally low amounts of blood plasma derived from donors having the blood group AB.
4. The blood plasma of claim 3, comprising
 - 6 to 10 parts of blood or blood plasma derived from donors having the blood group A,
 - 1 to 3 parts of blood or blood plasma derived from donors having the blood group B,
 - 0.0 to 1.5 parts of blood or blood plasma derived from donors having the blood group AB,
 - substantially no blood or blood plasma derived from donors having the blood group O.
5. The blood plasma of any one of the foregoing claims in liquid, frozen, or dried state.
6. The blood plasma of claim 5 in lyophilized or spray-dried form.

7. The blood or blood plasma of any one of the foregoing claims having pharmaceutically acceptable adjuvants, such as stabilizers and anticoagulants.
8. The blood or blood plasma of any one of the foregoing claims which blood plasma was subjected to a treatment for virus inactivation.
9. A process of preparing the blood or blood plasma of claim 1 comprising the steps of
 - pooling blood or blood plasma of donors having the blood groups A, and B,
 - optionally admixing blood or blood plasma of donors having the blood group AB,
 - optionally producing plasma from the blood or blood plasma pool,
 - neutralizing and/or removing ABO blood group specific antibodies.
10. The process of claim 9 further comprising the step of spray-drying or lyophilizing the plasma.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/04841

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 664 913 A (C.H. MIELKE ET AL.) 12 May 1987 see the whole document	1-10
A	EP 0 572 194 A (THE NEW YORK BLOOD CENTER, INC.) 1 December 1993 see the whole document	1-10
A	R. BERKOW ET AL. (ED.'S): "THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, FIFTEENTH EDITION" 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J. XP002054540 see page 1132, line 23 - line 25	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 December 1998

Date of mailing of the international search report

29/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 98/04841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4664913 A	12-05-1987	AU 596392 B	03-05-1990
		AU 6804987 A	04-08-1988
		EP 0276342 A	03-08-1988
		GR 3004763 T	28-04-1993
EP 572194 A	01-12-1993	AU 3864793 A	02-12-1993
		CA 2096654 A	29-11-1993
		JP 6100463 A	12-04-1994
		US 5541294 A	30-07-1996
		ZA 9303669 A	21-12-1993